Another biomarker, Ghrelin, was found to be increased in both presymptomatic GRN mutation carriers and FTD patients, suggesting that metabolic biomarker alterations may be associated with FTD progression [87]. The gene discussed is GHRL; the disease is frontotemporal dementia.